pegloticase
pegloticase: 2 clinical trials tracked.
pegloticase evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
What is verified about pegloticase, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (2)
A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout
Primary endpoint: Number of Participants Achieving Month 6 Response at Weeks 20, 21, 22, 23, and 24
A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (Pegloticase) Administered Every 4 Weeks Compared With KRYSTEXXA Administered Every 2 Weeks With Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants With Uncontrolled Refractory Gout (FORWARD II)
Primary endpoint: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6